Cytogenetics and fluorescence in situ hybridization as adjuncts to cytology in the diagnosis of malignant mesothelioma

Cancer Cytopathology

Volumn 117, Issue 4, 2009, Pages 247-253

  Factor, Rachel E ^a   Cin, Paola Dal ^a   Fletcher, Jonathan A ^a   Cibas, Edmund S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Ascites; Cytogenetics; Cytology; Effusions; Fluorescence in situ hybridization; Mesothelioma; Pleural fluid

Indexed keywords

ADULT; AGED; ARTICLE; CHROMOSOME ABERRATION; CYTOGENETICS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; HUMAN; KARYOTYPING; MALE; MESOTHELIOMA; METHODOLOGY; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; CHROMOSOME ABERRATIONS; CYTOGENETICS; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; MALE; MESOTHELIOMA; MIDDLE AGED;

EID: 69849115214     PISSN: None     EISSN: 19346638     Source Type: Journal    
DOI: 10.1002/cncy.20036     Document Type: Article

References (20)

1. Renshaw AA, Dean BR, Antman KH, Sugarbaker DJ, Cibas ES. The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Chest. 1997; 111:106-109.
2. Naylor B. The exfoliative cytology of diffuse malignant mesothelioma. J Pathol Bacteriol. 1963;86:293-298.
3. Ehya H. The cytologic diagnosis of mesothelioma. Semin Diagn Pathol. 1986;3:196-203.
4. Nguyen GK. Cytopathology of pleural mesotheliomas. Am J Clin Pathol. 2000;114(suppl):S68-S81.
5. Sherman ME, Mark EJ. Effusion cytology in the diagnosis of malignant epithelioid and biphasic pleural mesothelioma. Arch Pathol Lab Med. 1990;114:845-851.
6. Cibas ES, Corson JM, Pinkus GS. The distinction of adenocarcinoma from malignant mesothelioma in cell blocks of effusions: the role of routine mucin histochemistry and immunohistochemical assessment of carcinoembryonic antigen, keratin proteins, epithelial membrane antigen, and milk fat globule-derived antigen. Hum Pathol. 1987;18: 67-74.
7. Frisman DM, McCarthy WF, Schleiff P, Buckner SB, Nocito JD Jr, O'Leary TJ. Immunocytochemistry in the differential diagnosis of effusions: use of logistic regression to select a panel of antibodies to distinguish adenocarcinomas from mesothelial proliferations. Mod Pathol. 1993;6:179-184.
8. Ordonez NG. What are the current best immunohistochemical markers for the diagnosis of epithelioid mesothelioma? A review and update. Hum Pathol. 2007;38: 1-16.
9. Saad RS, Cho P, Liu YL, Silverman JF. The value of epithelial membrane antigen expression in separating benign mesothelial proliferation from malignant mesothelioma: a comparative study. Diagn Cytopathol. 2005;32:156-159.
10. Dejmek A, Hjerpe A. Reactivity of 6 antibodies in effusions of mesothelioma, adenocarcinoma and mesotheliosis: stepwise logistic regression analysis. Cytopathology. 2000;11: 8-17.
11. Cury PM, Butcher DN, Corrin B, Nicholson AG. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis. J Pathol. 1999;189:251-257.
12. Aerts JG, Delahaye M, van der Kwast TH, Davidson B, Hoogsteden HC, van Meerbeeck JP. The high post-test probability of a cytological examination renders further investigations to establish a diagnosis of epithelial malignant pleural mesothelioma redundant. Diagn Cytopathol. 2006; 34:523-527.
13. Roberts F, Harper CM, Downie I, Burnett RA. Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma. A study of thirteen antibodies. Am J Clin Pathol. 2001;116:253-262.
14. Attanoos RL, Griffin A, Gibbs AR. The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, plateletderived growth factor-receptor, P-glycoprotein and Bcl-2. Histopathology. 2003;43:231-238.
15. Granados R, Cibas ES, Fletcher JA. Cytogenetic analysis of effusions from malignant mesothelioma. A diagnostic adjunct to cytology. Acta Cytol. 1994;38:711-717.
16. Sandberg AA, Bridge JA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors. Mesothelioma. Cancer Genet Cytogenet. 2001;127:93-110.
17. Xiao S, Renshaw A, Cibas ES, Hudson TJ, Fletcher JA. Novel fluorescence in situ hybridization approaches in solid tumors. Characterization of frozen specimens, touch preparations, and cytological preparations. Am J Pathol. 1995;147:896-904.
18. Onofre FB, Onofre AS, Pomjanski N, Buckstegge B, Grote HJ, Bocking A. 9p21 Deletion in the diagnosis of malignant mesothelioma in serous effusions additional to immunocytochemistry, DNA-ICM, and AgNOR analysis. Cancer. 2008;114:204-215.
19. Chiosea S, Krasinskas A, Cagle PT, Mitchell KA, Zander DS, Dacic S. Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas. Mod Pathol. 2008;21: 742-747.
20. Shin HJ, Shin DM, Tarco E, Sneige N. Detection of numerical aberrations of chromosomes 7 and 9 in cytologic specimens of pleural malignant mesothelioma. Cancer. 2003;99:233-239.